Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Metastatic Castrate- Resistant Prostate Cancer 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 75Paclitaxel 68Bevacizumab 44Taxes 22Cyclophosphamide 21pembrolizumab 19Gemcitabine 19Cisplatin 18Topotecan 17Hyperthermic Intraperitoneal Chemotherapy 14olaparib 13liposomal doxorubicin 13Immunoglobulin G 13Disulfides 13Specimen Handling 11Drug Therapy 11niraparib 10Cytoreduction Surgical Procedures 10Magnetic Resonance Spectroscopy 9sargramostim 7Surveys and Questionnaires 7Doxorubicin 7Docetaxel 7durvalumab 6Platinum 6Nivolumab 6Letrozole 6Granulocyte-Macrophage Colony-Stimulating Factor 6Biopsy 6Albumin-Bound Paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Fallopian Tube Neoplasms × phenoxodiol × Clear all
NCT00303888 2018-01-17

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Yale University

Phase 1 Terminated
31 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡